Cargando…

Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies

The main binding site for SARS-COV-2 spike protein in human body is human Angiotensin converting enzyme 2 (ACE2) protein receptor. Herein we present the effect of chloroquine (CLQ) on human ACE2 receptor. Molecular docking studies showed that chloroquine have a docking score is quite high compare to...

Descripción completa

Detalles Bibliográficos
Autores principales: Baildya, Nabajyoti, Ghosh, Narendra Nath, Chattopadhyay, Asoke P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831893/
https://www.ncbi.nlm.nih.gov/pubmed/33518803
http://dx.doi.org/10.1016/j.molstruc.2021.129891
_version_ 1783641715356205056
author Baildya, Nabajyoti
Ghosh, Narendra Nath
Chattopadhyay, Asoke P.
author_facet Baildya, Nabajyoti
Ghosh, Narendra Nath
Chattopadhyay, Asoke P.
author_sort Baildya, Nabajyoti
collection PubMed
description The main binding site for SARS-COV-2 spike protein in human body is human Angiotensin converting enzyme 2 (ACE2) protein receptor. Herein we present the effect of chloroquine (CLQ) on human ACE2 receptor. Molecular docking studies showed that chloroquine have a docking score is quite high compare to other well known drugs. Furthermore, molecular dynamics (MD) studies with CLQ docked ACE2 results in large fluctuations on RMSD up to 2.3 ns, indicating conformational and rotational changes due to the presence of drug molecule in the ACE2 moiety. Analysis of results showed that CLQ can effect the conformation of human ACE2 receptor. We believed that this work will help researchers to understand better the effect of CLQ on ACE2.
format Online
Article
Text
id pubmed-7831893
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-78318932021-01-26 Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies Baildya, Nabajyoti Ghosh, Narendra Nath Chattopadhyay, Asoke P. J Mol Struct Article The main binding site for SARS-COV-2 spike protein in human body is human Angiotensin converting enzyme 2 (ACE2) protein receptor. Herein we present the effect of chloroquine (CLQ) on human ACE2 receptor. Molecular docking studies showed that chloroquine have a docking score is quite high compare to other well known drugs. Furthermore, molecular dynamics (MD) studies with CLQ docked ACE2 results in large fluctuations on RMSD up to 2.3 ns, indicating conformational and rotational changes due to the presence of drug molecule in the ACE2 moiety. Analysis of results showed that CLQ can effect the conformation of human ACE2 receptor. We believed that this work will help researchers to understand better the effect of CLQ on ACE2. Elsevier B.V. 2021-04-15 2021-01-07 /pmc/articles/PMC7831893/ /pubmed/33518803 http://dx.doi.org/10.1016/j.molstruc.2021.129891 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Baildya, Nabajyoti
Ghosh, Narendra Nath
Chattopadhyay, Asoke P.
Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies
title Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies
title_full Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies
title_fullStr Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies
title_full_unstemmed Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies
title_short Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies
title_sort inhibitory capacity of chloroquine against sars-cov-2 by effective binding with angiotensin converting enzyme-2 receptor: an insight from molecular docking and md-simulation studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831893/
https://www.ncbi.nlm.nih.gov/pubmed/33518803
http://dx.doi.org/10.1016/j.molstruc.2021.129891
work_keys_str_mv AT baildyanabajyoti inhibitorycapacityofchloroquineagainstsarscov2byeffectivebindingwithangiotensinconvertingenzyme2receptoraninsightfrommoleculardockingandmdsimulationstudies
AT ghoshnarendranath inhibitorycapacityofchloroquineagainstsarscov2byeffectivebindingwithangiotensinconvertingenzyme2receptoraninsightfrommoleculardockingandmdsimulationstudies
AT chattopadhyayasokep inhibitorycapacityofchloroquineagainstsarscov2byeffectivebindingwithangiotensinconvertingenzyme2receptoraninsightfrommoleculardockingandmdsimulationstudies